Altimmune, Inc. (NASDAQ:ALT - Free Report) - Research analysts at HC Wainwright lowered their Q1 2024 earnings estimates for Altimmune in a report released on Monday, April 1st. HC Wainwright analyst P. Trucchio now anticipates that the company will post earnings of ($0.34) per share for the quarter, down from their previous forecast of ($0.29). HC Wainwright has a "Buy" rating and a $12.00 price target on the stock. The consensus estimate for Altimmune's current full-year earnings is ($1.44) per share. HC Wainwright also issued estimates for Altimmune's Q2 2024 earnings at ($0.35) EPS, Q3 2024 earnings at ($0.35) EPS, Q4 2024 earnings at ($0.33) EPS, FY2024 earnings at ($1.37) EPS, Q1 2025 earnings at ($0.39) EPS, Q2 2025 earnings at ($0.40) EPS, Q3 2025 earnings at ($0.40) EPS, Q4 2025 earnings at ($0.38) EPS, FY2025 earnings at ($1.57) EPS, FY2026 earnings at ($1.67) EPS, FY2027 earnings at ($1.65) EPS and FY2028 earnings at ($0.15) EPS.
A number of other research firms have also weighed in on ALT. B. Riley reiterated a "buy" rating and issued a $20.00 price target on shares of Altimmune in a research report on Thursday, March 28th. The Goldman Sachs Group began coverage on shares of Altimmune in a research report on Wednesday, January 24th. They issued a "neutral" rating and a $13.00 price target for the company.
Check Out Our Latest Research Report on ALT
Altimmune Trading Down 4.2 %
NASDAQ ALT traded down $0.39 during trading hours on Thursday, hitting $8.90. 3,049,282 shares of the company's stock traded hands, compared to its average volume of 5,917,689. The business's fifty day moving average price is $9.91 and its two-hundred day moving average price is $6.94. The firm has a market capitalization of $478.20 million, a P/E ratio of -5.63 and a beta of 0.05. Altimmune has a 52 week low of $2.09 and a 52 week high of $14.84.
Hedge Funds Weigh In On Altimmune
Hedge funds and other institutional investors have recently modified their holdings of the stock. Barclays PLC raised its stake in Altimmune by 62.0% during the third quarter. Barclays PLC now owns 180,409 shares of the company's stock valued at $470,000 after purchasing an additional 69,014 shares in the last quarter. GSA Capital Partners LLP raised its stake in Altimmune by 153.1% during the third quarter. GSA Capital Partners LLP now owns 445,868 shares of the company's stock valued at $1,159,000 after purchasing an additional 269,676 shares in the last quarter. Dark Forest Capital Management LP raised its stake in Altimmune by 13.4% during the third quarter. Dark Forest Capital Management LP now owns 230,353 shares of the company's stock valued at $599,000 after purchasing an additional 27,210 shares in the last quarter. Keudell Morrison Wealth Management purchased a new stake in Altimmune during the third quarter valued at $36,000. Finally, WealthPlan Investment Management LLC purchased a new stake in Altimmune during the third quarter valued at $31,000. Institutional investors own 78.05% of the company's stock.
Altimmune Company Profile
(
Get Free Report)
Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and non-alcoholic steatohepatitis.
Featured Articles
Before you consider Altimmune, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Altimmune wasn't on the list.
While Altimmune currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
